Arcutis Biotherapeutics, Inc.

ARQT Healthcare Biotechnology

Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024. In the quarter to June 2026, revenue grew 59.3%, EPS grew 184.6%, free cash flow grew 228.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

28.82 0.28 −0.96%
Market cap
$3.7B
P/E
131×
Fwd P/E
196×
Dividend yield
—
F-score
4/9
Altman Z
6.98
Beneish M
−1.52
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
7 6 4 6

+8 more TTM periods

ROE
15.86% (1.43%) (9.30%) (28.17%)
ROA
6.78% (0.59%) (4.13%) (10.97%)
ROIC
23.62% 2.69% (9.91%) (31.79%)
Return on Tangible Assets
9.25% (0.86%) (5.71%) (17.68%)
Average Days of Receivables
122.06 126.79 141.92 132.16
Free Cash Flow per Share
0.30 0.21 (0.17) (0.38)
Free Cash Flow
39.07 26.99 (21.31) (48.24)
Capital Expenditures
(0.24) — (15.69) (15.69)
Other line items
Cash ROIC
6.87% 5.16% (4.10%) (10.53%)
Accounts Receivable Turnover
3.54 3.62 3.43 3.63
Accounts Payable Turnover
3.79 1.76 2.74 2.54
Inventory Turnover
1.49 1.39 1.98 1.75
Average Days of Payables
58.65 177.38 124.61 66.28
Days of Inventory on Hand
345.31 362.50 225.14 256.42
Tax Rate
(0.03) 0.71 0.08 0.02
Research and Development Expense of Revenue
19.62% 21.69% 20.49% 22.36%
Selling, General and Administrative Expense of Revenue
64.14% 68.48% 73.01% 79.64%
Share Based Compensation of Revenue
9.39% 9.93% 10.73% 12.49%
Interest Coverage
2.47 0.24 (1.01) (2.61)
Operating CF/Net income
1.38 (11.36) 0.35 0.73
Depreciation/Fixed assets
1.50 0.80 2.47 1.00
Capex/Depreciation
(0.18) 0.00 (6.10) (12.90)
Revenue per Share
3.55 3.21 2.96 2.49
Operating CF per Share
0.30 0.21 (0.04) (0.26)
Capex per Share
0.00 0.00 (0.12) (0.12)
Capex to Sales
0.00 0.00 0.04 0.05

Fold the line items

Columns are period end dates